SACS: A Potential Drug Target and Biomarker for Diseases (G26278)

Target Name: SACS

NCBI ID: G26278

SACS

SACS: A Potential Drug Target and Biomarker for Diseases

SACS, or sulfate-binding protein, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the DNAJ homolog subfamily C and is characterized by its unique structure and subcellular localization. SACS has been identified as a potential drug target and may serve as a biomarker for certain diseases.

SACS is a protein that is expressed in a variety of tissues, including muscle, heart, and brain. It is typically synthesized in the cytoplasm and is localized to the endoplasmic reticulum, where it can be targeted by various vesicular transport systems. SACS is also Characterized by its unique structure, which consists of a long extracellular domain and a short intracellular domain.

One of the unique features of SACS is its ability to interact with a variety of different molecules, including transcription factors and signaling proteins. This interaction between SACS and these molecules makes it a potentially interesting drug target. Additionally, SACS is characterized by its ability to modulate the activity of various cellular signaling pathways, which may make it a useful biomarker for certain diseases.

SACS has been shown to play a role in a number of different cellular processes, including the regulation of gene expression, cell signaling, and the development of cancer. For example, studies have shown that SACS can interact with the transcription factor NF-kappa-B and can modulate its activity. This interaction between SACS and NF-kappa-B suggests that SACS may be a useful target for drugs that are designed to inhibit NF-kappa-B signaling.

In addition to its potential role as a drug target, SACS is also a potential biomarker for certain diseases. For example, studies have shown that SACS is expressed in a variety of tissues and that its levels can be affected by a variety of different factors, including stress, exercise, and certain medications. This suggests that SACS may be a useful biomarker for certain diseases, such as heart disease or cancer.

SACS is also characterized by its unique cellular sub localization, which is a hallmark of the DNAJ homolog subfamily C. This subfamily includes a variety of proteins that are characterized by their ability to interact with the transcription factor TF-DNA and by their subcellular localization in the nucleic acid. SACS is one of the best-known members of this subfamily and its subcellular localization is a hallmark of its DNAJ homolog identity.

In conclusion, SACS is a protein that is characterized by its unique structure and subcellular localization. It is expressed in a variety of tissues and has been shown to play a role in the regulation of gene expression, cell signaling, and the development of cancer. Additionally, SACS is a potential drug target and may serve as a biomarker for certain diseases. Further research is needed to fully understand the role of SACS in cellular processes and its potential as a drug and biomarker.

Protein Name: Sacsin Molecular Chaperone

Functions: Co-chaperone which acts as a regulator of the Hsp70 chaperone machinery and may be involved in the processing of other ataxia-linked proteins

The "SACS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SACS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets